OncoMatch

OncoMatch/Clinical Trials/NCT05837455

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Is NCT05837455 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for breast cancer.

Phase 2RecruitingWashington University School of MedicineNCT05837455Data as of May 2026

Treatment: VENTANA MIB-1 Ki67 assay · Oncotype DX® Recurrence Score · PAM50-based Prosigna breast cancer gene signature assay · Anastrozole · Combination anthracycline and/or taxane based treatmentThis study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 overexpression (ER > 10%)

ER-positive (ER > 10%)

Required: HER2 (ERBB2) negative (IHC 0 or 1+ or FISH negative)

HER2 negative must be assessed by FISH or IHC staining 0 or 1+ according to ASCO/CAP guidelines

Disease stage

Required: Stage II, III (AJCC 8th edition)

Excluded: Stage CT4D, CM1

clinical stage II or III (by AJCC 8th edition - at least T2, any N, M0 or if N1+ then any T)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: systemic therapy

Lab requirements

Blood counts

Adequate bone marrow function, as determined by the treating physician

Kidney function

Adequate organ function, as determined by the treating physician

Liver function

Adequate organ function, as determined by the treating physician

Adequate bone marrow and organ function, as determined by the treating physician

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Washington University School of Medicine · St Louis, Missouri

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify